Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Opdivo wins speedy FDA approval in lung cancer

This article was originally published in Scrip

Executive Summary

Just days after Bristol-Myers Squibb revealed it had won a priority review from the FDA for the firm's application for Opdivo (nivolumab) as a treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy, regulators made a stunning announcement that the agency had granted approval.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027997

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel